Ritanserin in the treatment of alcohol dependence - A multi-center clinical trial

Psychopharmacology

Volumn 128, Issue 2, 1996, Pages 206-215

  Johnson, Bankole A ^a   Jasinski, Donald R ^b   Galloway, Gantt P ^c   Kranzler, Henry ^d   Weinreib, Robert ^e   Anton, Raymond F ^f   Mason, Barbara J ^g   Bohn, Michael J ^h   Pettinati, Helen M ^e   Rawson, Richard ⁱ   Clyde, Christopher ^j  

^a UNIVERSITY OF TEXAS   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^c Haight Ashbury Free Clinics   (United States)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

ⁱ Matrix Center   (United States)

^j JANSSEN RESEARCH AND DEVELOPMENT   (United States)

more..

Author keywords

5 HT2 antagonist; alcoholism; clinical trial; humans; multi center; pharmacotherapy; ritanserin; serotonin (5 HT)

Indexed keywords

PLACEBO; RITANSERIN; SEROTONIN 2 ANTAGONIST;

ADDICTION; ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADULT; ALCOHOLISM; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HUMANS; MALE; MIDDLE AGED; RHINITIS; RITANSERIN; SEROTONIN ANTAGONISTS; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 10544253845     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050126     Document Type: Article

References (71)

1. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders (3rd edn revised). American Psychiatric Association, Washington DC
2. 2 receptors
3. Anton R, Moak DH (1994) Carbohydrate deficient transferrin and γ-glutamyltransferase as markers of heavy alcohol consumption: gender differences. Alcohol Clin Exp Res 18: 747-754
4. 2 antagonist. Drug Dev Res 5: 61-73
5. Balldin J, Berggren U, Engel J, Ericksson M, Hard E, Soderpalm B (1994) Effect of citalopram on alcohol intake in heavy drinkers. Alcohol Clin Exp Res 18:1133-1136
6. Bandura A (1977) Self-efficacy: toward a unifying theory of behavioral change. Psychological Rew 84:191-215
7. Bandura A (1981) Self-referent thought: a developmental analysis of self-efficacy. In: Flavell JH, Ross L (eds) Social cognitive development frontiers and possible futures. Cambridge University Press, Cambridge
8. Bandura A (1982) Self-efficacy mechanism in human agency. Am Psychol 37:122-147
9. 3 anatagonists fail to affect ethanol self-administration of rats. Alcohol 11:389-395
10. Brady JP, Foulks ET, Childress AR, Petschuk M (1982) The Michigan Alcoholism screening test as a survey instrument. J Operation Psychiatry 13:27-31
11. Bruno F (1989) Buspirone in the treatment of alcoholic patients. Psychopathology 22 [suppl.]:49-59
12. Buydens-Branchey L, Branchey MH, Noumair D, Lieber CS (1989) Age of alcoholism onset: II. relationship of susceptibility to serotonin precursor availability. Arch Gen Psychiatry 46: 231-236
13. Carlsson AV, Hiltunen AJ, Beck O, Stibler H, Borg S (1993) Detection of relapses in alcohol-dependent patients: comparison of CDT in serum, 5-hydroxytryptophol in urine, and self-reports. Alcohol Clin Exp Res 17:703-708
14. Cooney NL, Kadden RM, Litt MD, Getter H (1991) Matching alcoholics to coping skills or interactional therapies. J Consult Clin Psychol 59:598-601
15. Darbar D, Luck J, Davidson N, Pringle T, Ain GM, McNeill, G, Struthers AD (1996) Sensitivity and specifictiy of QTc dispersion for identification of risk of cardiac death in patients with peripheral vascular disease. BMJ 312:874-877
16. Di Chiara G (1992) The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend 38:95-137
17. Doty P, Zachny JP, de Wit H (1994) Effects of ondansetron pretreatment on acute responses to ethanol in social drinkers. Behav Pharmacol 5:461-469
18. Fadda F, Mosca E, Colombo G, Gessa GL (1989) Effects of spontaneous ingestion of ethanol on brain dopamine metabolism. Physiol Behav 47:727-729
19. 3 receptor antagonist, suppresses voluntary ethanol consumption in alcohol-preferring rats. Alcohol Alcohol 26:107-110
20. Gerra G, Caccavari R, Delsignore R, Bocchi R, Fertonani G, Passeri M (1992) Effects of fluoxetine and Ca-acetyl-homotaurinate on alcohol intake in familial and non-familial alcoholic patients. Curr Ther Res 52:291-295
21. Gorelick DA, Paredes A (1992) Effects of fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res 16: 261-265
22. Guy W (1976) ECDEU assessment for psychopharmacology revised. DHEW Publication No.(ADM) NIMH: Rockville 76-338
23. Hervé D, Pickel VM, Joh TH, Beaudet A (1987) Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res 435:71-83
24. 3 antagonist ICS 205-930. Alcohol 10:191-196
25. Hollingshead A B, Redlich F C (1958) Social class and mental illness: a community study. Wiley, New York
26. Investigational New Drug Brochure (1993) Ritanserin (R 55 667). Janssen Research Foundation
27. 3 receptor interactions in animals and humans. Drug Dev Res 30:153-169
28. 3 receptor blockade; a preliminary study in healthy male volunteers. Psychopharmacology 112: 142-144
29. Kadden RM, Cooney NL, Getter H, Litt MD (1989) Matching alcoholics to coping skills or interactional therapies: post-treatment results. J Consult Clin Psychol 57:698-704
30. 3 receptor antagonist, reduces voluntary ethanol consumption in rats. Pharmacol Biochem Behav 41:847-850
31. Koob GF (1992) Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 131:177-184
32. Kranzler HR, Burleson JA, Del Boca FK, Babor TF, Korner P, Brown J, Bohn MJ (1994) Buspirone in the treatment of anxious alcoholics. A placebo-controlled trial. Arch Gen Psychiatry 51:720-731
33. Kranzler HR, Burleson JA, Del Boca FK, Bohn MJ, Brown J, Liebowitz N (1995) Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention. Am J Psychiatry 152:391-397
34. Linnoila MI, Virkkunnen M (1992) Aggression, suicidality, and serotonin. J Clin Psychiatry 53 [suppl.]:46-51
35. Litten RZ, Allen J (1996) Mediacational aids to treat alcohol problems. In: Johnson BA, Roache J (eds) Drug addition and its treatment: Nexus of neuroscience and behavior. Raven Press, New York (in press)
36. Malcolm R, Anton RF, Randall CL, Johnston A, Brady K, Thevos A (1992) A placebo-controlled trial of buspirone in anxious alcoholics. Alcohol Clin Exp Res 16:1007-1113
37. McLellan AT, Parikh G, Bragg A, Cacciola J, Fureman B, Incmikoski R (1980) Addiction severity index, administration manual, 5th edn. Penn-VA Centers for Studies of Addiction
38. McLellan AT, Luborsky L, Cacciola J, Griffiths J, Evans F, Barr H, O'Brien C (1986) New data from the addiction severity index: reliability and validity scores from three centers. J Nerv Ment Dis 173:412-423
39. Meert TF, Awouters F, Niemegeers CJE, Schellekens KHL, Janssen PAJ (1991) Ritanserin reduces abuse of alcohol, cocaine, and fentanyl in rats. Pharmacopsychiatry 24:159-163
40. Marlatt GA, Gordon JR (1985) Relapse prevention. Guildford Press, New York
41. Meuldermans W, Torfs B, Heykants J (1984) The plasma protein binding of ritanserin (R 55 667) and its distribution in blood. Interim Report, Janssen Research Foundation
42. Monti JM, Alterwain P (1991) Ritanserin decreases alcohol intake in chronic alcoholics. Lancet 337:60
43. Monti PM, Abrams DB, Kadden R, Cooney N (1989) Treating alcohol dependence: a coping skills therapy guide. Guildford Press, New York
44. Myers RD, Lankford M, Bjork A (1992) Selective reduction by the 5-HT antagonist amperozide of alcohol preference induced in rats by systemic cyanamide. Pharmacol Biochem Behav 43:661-667
45. Myers RD, Lankford M, Bjork A (1993) Irreversible suppression of alcohol drinking in cyanamide-treated rats after sustained delivery of the 5-HT-sub-2 antagonist amperozide. Alcohol 10[2]:117-125
46. Naranjo CA, Sellers EM, Roach CA, Woodley DV, Sanchez-Craig M, Sykora K (1984) Zimeledine-induced variations in alcohol intake by non-depressed heavy drinkers. Clin Pharmacol Exp Ther 35:374-381
47. Naranjo CA, Sellers EM, Sullivan JT, Woodley DV, Kadlec K, Sykora K (1987) The serotonin re-uptake inhibitor citalo pram attenuates ethanol intake. Clin. Pharmacol Ther 41: 266-274
48. Naranjo CA, Sullivan JT, Kadlec K, Woodley-Remus DV, Kennedy G, Sellers EM (1989) Differential effects of viqualine on alcohol intake and other consummatory behaviors. Clin Pharmacol Ther 46:301-309
49. Naranjo CA, Kadlec KE, Sanhueza P, Woodley-Remus DV, Sellers EM (1990) Fluoretine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clin Pharmacol Ther 47:490-498
50. 2 antagonist, in heavy social drinkers: desire to drink, alcohol intake and related effects. Addiction 90:893-905
51. Niemelä O, Sorvajärvi K, Blake JE, Israel Y (1995) Carbohydrate deficient transferrin as a marker of alcohol abuse: relationship to alcohol consumption, severity of liver disease, and fibrogenesis. Alcohol Clin Exp Res 19:1203-1208
52. Oakley NR, Jones BJ, Tyers MB, Costall B, Domeney AM (1988) The effects of GR 38032F on alcohol consumption in the marmoset. Br J Pharmacol 95:870P
53. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992) Naltrexone coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 49: 881-887
54. Project MATCH Research Group (1993) Project MATCH: rationale and methods for multi-site clinical trial matching patients to alcoholism treatment.Alcohol Clin Exp Res 17: 1130-1145
55. SAS (1989) SAS/STAT Users guide, version 6, 4th edition, volume 1. SAS Institute, SAS Campus Drive, Cary, NC 27513
56. Selzer ML (1971) The Michigan Alcoholism Screening test: the quest for a new diagnostic instrument. Am J Psychiatry 127: 1653-1658
57. Sobell LC, Sobell MB (1992) Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten R, Allen J (eds) Measuring alcohol consumption, Human Press, Clifton, N.J., pp 41-72
58. Spitzer RL, Williams JBW, Gibbon M, First MB (1992) The structured clinical interview for DSM-III-R (SCID), I: history, rationale, and description. Arch Gen Psychiatry 49:624-629
59. Stibler H (1991) Carbohydrate-deficient transferrin in serum: a new marker of potentially harmful alcohol consumption reviewed. Clin Chem 37:2029-2037
60. Stibler H, Hulcrantz R (1987) CDT in serum in patients with liver diseases. Alcohol Clin Exp Res 11:468-473
61. Stibler H, Borg S, Beckman G (1988) Transferrin phenotype and level of CDT in healthy individuals. Alcohol Clin Exp Res 12:450-453
62. Stibler H, Borg S, Joustra M (1991) A modified method for the assay of CDT in serum. Alcohol Alcohol Suppl:451-454
63. Svensson L, Fahike C, Hard E, Engel JA (1993) Involvement of serotonergic systems in ethanol intake in the rat. Alcohol 10:219-224
64. Swift R, Kuzenetsov O, Whelihan W (1994) Ondansetron modifies ethanol intoxication in humans. 32nd Annual Meeting of the Amerian College of Neropsychiatry
65. Tollefson GD, Montague-Clouse J, Tollefson SL (1992) Treatment of co-morbid generalized anxeity in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). J Clin Psychopharmacol 12:19-26
66. Tyrer P (1990) Personality disorder and social functioning. In: Peck DF, Shapiro CM (eds) Measuring human problems, a practical guide revised. Peck DF, DWHE Publications (ADM) NIMH, Rockville, pp 218-222
67. 2 receptor antagonist activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 98: 45-50
68. US Department of Health and Human Services (1992) Cognitive-behavioral coping skills therapy. NIAAA Project Monograph Series 3, Washington DC
69. Van Peer A, Gasparini R, Woestenborgs R, Heykants J, Gelders Y (1985) Pharmacokinetics and oral bioavailability of ritanserin (R 55 667) after intravenous and oral administration in healthy volunteers. Clinical Research Report on R 55 667/3, Janssen Research Foundation
70. Vande Velde P, Van Rooy P, Gelders Y, Van Peer A, Woestenborgs R, Heykants J, Vanden-Bussche G (1987) Multiple-dose pharmacokinetics and dose proportionality of ritanserin after oral administration of 5, 10, and 20 mg once daily for 7 days to healthy volunteers. Clinical Research Report, Janssen Research Foundation
71. Wise RA, Bozarth MA (1987) A psychostimulant theory of addiction. Psychol Rev 94:469-492